Syngene Broadens Bristol Myers Squibb Research Tie-Up

Syngene International on Monday announced that it has extended its long-term Bristol Myers Squibb partnership through 2035, deepening one of the longest-running collaborations in the global contract research space.

The expanded agreement strengthens Syngene International Bristol Myers Squibb partnership across the full drug development lifecycle, from early discovery to commercialization.

Under the renewed deal, the collaboration will now cover a broader range of integrated services, including discovery research, translational sciences, pharmaceutical development, manufacturing, clinical trials, and data and information technology services. Syngene said this end-to-end approach will help ensure smoother progression of drug programs from research labs to commercial production.

Also Read: How a Culture of Thanks Fuels Retention in Hospitals

The company said the expansion marks the next phase of growth in the partnership and reinforces its role as a strategic, long-term partner delivering integrated scientific and manufacturing solutions.

"Our collaboration with Bristol Myers Squibb, which now spans more than 25 years, is anchored in scientific excellence, operational reliability, and a shared commitment to advancing innovative therapies," Syngene International Managing Director and CEO Peter Bains stated.

Bains added that extending the partnership through 2035 allows both companies to plan future capabilities and infrastructure with a clear, decade-long view. "We look forward to supporting BMS with their next wave of discovery, development, and manufacturing programs that have the potential to improve patient outcomes worldwide," he stated.

The Syngene International Bristol Myers Squibb partnership began in 1998 and led to the creation of the Biocon Bristol Myers Squibb Research and Development Center, Syngene’s first dedicated R&D facility, which became fully operational in 2009.

"This expanded collaboration reflects our commitment to advancing innovative science by effective integration of our research, development, and manufacturing capabilities to accelerate the delivery of transformative medicines and bring hope to patients around the world who are waiting for new treatment options," Bristol Myers Squibb Senior VP Therapeutic Discovery Sciences Payal Sheth stated.